Cardiac Rhythm Management
banner AtriCure HRS2018 Achieving Optimal Outcomes

 

Activity Description

This enduring educational activity reviews existing practice gaps with traditional Atrial Fibrillation treatment strategies, and examines the structural mechanistic basis of Persistent Atrial Fibrillation, and clinical evidence supporting Hybrid Endocardial/Epicardial Ablation and Posterior Wall Isolation. The leading experts also evaluate the rationale and design of the CONVERGE and DEEP Trials.

This activity was created from the live proceedings of a satellite symposium held at Heart Rhythm 2018.


 

Access Presentation

Webcast

Click on the session title listed below to view each presentation.

tmb webcast AtriCureHRS2018 K Makati pres

Insights into the Structural and Mechanistic Basis of Persistent Atrial Fibrillation: Arguments Supporting Hybrid Endocardial/Epicardial Ablation and Posterior Wall Isolation.
Kevin Makati, MD, FACC, FHRS

play-webcast

tmb webcast AtriCureHRS2018 D Delurgio pres

Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF
David DeLurgio, MD, FACC, FHRS

play-webcast

tmb webcast AtriCureHRS2018 K Ellenborgen pres

DEEP Trial: Hybrid Ablation
Kenneth Ellenbogen, MD

play-webcast

tmb webcast AtriCureHRS2018 panel

Panel Discussion
Panel: David DeLurgio, MD, FACC, FHRS, Kenneth Ellenbogen, MD, Kevin Makati, MD, FACC, FHRS

play-webcast

 


Commercial Supporter

This activity is supported by an educational grant from AtriCure

Joint-Providers

MediaSphere Medical, LLC and Ciné-Med

 

Faculty

Faculty

tmb webcast AtriCureHRS2018 D Delurgio port

David DeLurgio, MD, FACC, FHRS
Professor of Medicine
Division of Cardiology, Department of Medicine
Emory University School of Medicine
Atlanta, GA

tmb webcast AtriCureHRS2018 K Ellenborgen port

Kenneth Ellenbogen, MD
Martha M. and Harold W. Kimmerling Professor of Cardiology
Chair, Cardiology
VCU School of Medicine
Richmond, VA

tmb webcast AtriCureHRS2018 K Makati port

Kevin Makati, MD, FACC, FHRS
Rhythm Section Chairperson, Baycare Health Systems
Co-Director Arrhythmia Department, St. Joseph’s Hospital
Tampa, FL

 

 

CME/CE Test
  1. Achieving Optimal Outcomes for Persistent Atrial Fibrillation Patients through Hybrid Ablation
  2. Please enter your information, and complete the following CME post test and evaluation form. Upon successful completion, your submission will be reviewed and you will receive notification shortly regarding the status of your certificate. You must achieve a minimum score of 70% to earn credit for this activity.

  3. First Name: *  
    Invalid Input
  4. Last Name: *  
    Invalid Input
  5. Primary Email Address: *  
    Invalid Input
  6. Confirm Your Email: *  
    Invalid Input
  7. Degree: *  
    Invalid Input
  8. Institution: *  
    Invalid Input
  9. Mailing Address:*  
    Invalid Input
  10. City: *  
    Invalid Input
  11. State: *  
    Invalid Input

  12. 1. The posterior wall has been shown to harbor AF triggers, and proves to be a viable ablation target.
  13. Select one*  


    Invalid Input Please Select one

  14. 2. Ablation of the posterior wall decreases AF beyond PVI.
  15. Select one*  


    Invalid Input Please Select one

  16. 3. The study purpose of the CONVERGE IDE Clinical Trial is to evaluate the safety and efficacy of the Epi-Sense® - AF Guided Coagulation System with VisiTrax® for the treatment of symptomatic persistent Atrial Fibrillation (AF) patients refractory or intolerant to at least one Class I and/or Class III anti-arrhythmic drug (AAD).
  17. Select one*  


    Invalid Input Please Select one

  18. 4. The objective of the DEEP Pivotal Trial is to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with Persistent AF or Longstanding AF.
  19. Select one*  


    Invalid Input Please Select one

  20. 5. The primary effectiveness endpoint of the DEEP Trial is freedom from any documented AF, atrial flutter, or atrial tachycardia lasting >30 seconds in duration through the 12 month follow-up visit in the absence of Class I or III AADs (with exception of previously failed AADs at doses not exceeding those previously failed.
  21. Select one*  


    Invalid Input Please Select one

  22. 6. Atrio-esophageal fistula (AEF) is a rare complication which can occur in any procedure that involves ablation near the posterior wall of the left atrium.
  23. Select one*  


    Invalid Input Please Select one

  24. 7. Which risk mitigating actions proposed to the FDA to reduce the risk of AEF is accurate?
  25. Select one*  






    Invalid Input Please Select one

  26. Although optional, we respectfully request that you complete the activity evaluation form, since your feedback assists in the development of future educational activities.

  27. Background

    Please rate each question using a scale of 1 to 5 (1 = Beginner, 5 = Advanced)


  28. I would consider my level of expertise in the subject matter prior to the webcast as:
    Invalid Input Please Select one

  29. I would consider my level of expertise in the subject matter after the activity
    Invalid Input

  30. Considering my experience and background, the material presented was:
    Invalid Input Please Select one

  31. Extent to which activity met the identified objectives
    Please rate each question using a scale of 1 to 5 (1 = Not Met, 5 = Completely Met)

  32. Review structural and mechanistic basis of Persistent Atrial Fibrillation, and clinical evidence supporting Hybrid Endocardial/Epicardial Ablation and Posterior Wall Isolation.
    Invalid Input Please Select one

  33. Evaluate the rationale and design of the CONVEREGE Trial for the treatment of Symptomatic Persistent Atrial Fibrillation.
    Invalid Input Please Select one

  34. Examine the rationale and design of the DEEP Trial for the treatment of subjects with Persistent or Longstanding Persistent Atrial Fibrillation.
    Invalid Input Please Select one

  35. Information Presented
    Please evaluate the information that was presented by answering Yes, No, Maybe or Not Applicable

  36. Reinforced my current practice/treatment habits:
    Invalid Input Please Select one

  37. Will improve my practice/patient outcomes:
    Invalid Input Please Select one

  38. Enhanced my current knowledge base:
    Invalid Input Please Select one

  39. Provided new ideas or information that I expect to use:
    Invalid Input Please Select one

  40. Information gained from this conference will result in making a change in your practice:
    Invalid Input Please Select one

  41. Future activities on this subject matter is important to my practice:
    Invalid Input Please Select one

  42. Addressed a professional practice gap:
    Invalid Input Please Select one

  43. Was free of commercial bias/influence:
    Invalid Input Please Select one

  44. What barriers do you anticipate in incorporating best practices learned in this activity into clinical activities or quality improvement initiatives at your institution?
    Invalid Input

  45. What mechanisms can you identify to overcome these barriers?
    Invalid Input

  46. (*) Required Fields
  47. Invalid Input